Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.

about

Ubiquitylation at the Fork: Making and Breaking Chains to Complete DNA Replication

P2860

Q59138263-B247A342-18D7-4DF5-B742-B8724A2A9034

P2860

Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.

Item

http://www.wikidata.org/entity/Q43973311

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Suppression of the FA pathway ...... g cancer cells to gemcitabine.

@en

Suppression of the FA pathway ...... g cancer cells to gemcitabine.

@nl

type

Item

label

Suppression of the FA pathway ...... g cancer cells to gemcitabine.

@en

Suppression of the FA pathway ...... g cancer cells to gemcitabine.

@nl

prefLabel

Suppression of the FA pathway ...... g cancer cells to gemcitabine.

@en

Suppression of the FA pathway ...... g cancer cells to gemcitabine.

@nl

P1476

Suppression of the FA pathway ...... g cancer cells to gemcitabine.

@en

P2093

Chun-Hua Dai

http://www.w3.org/2001/XMLSchema#string

Jian Li

http://www.w3.org/2001/XMLSchema#string

Jin-Yu Su

http://www.w3.org/2001/XMLSchema#string

Mei-Yu Li

http://www.w3.org/2001/XMLSchema#string

Ping Chen

http://www.w3.org/2001/XMLSchema#string

Qian Jiang

http://www.w3.org/2001/XMLSchema#string

Ting Lan

http://www.w3.org/2001/XMLSchema#string

Yan Wu

http://www.w3.org/2001/XMLSchema#string

Yi Wang

http://www.w3.org/2001/XMLSchema#string

P2860

The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage

ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1

Interplay between Fanconi anemia and homologous recombination pathways in genome integrity

Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].

Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics

The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage

Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.

P2888

s41598-017-15172-4

P304

15031

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-15172-4

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092504165

http://www.w3.org/2001/XMLSchema#string

P698

29118324

http://www.w3.org/2001/XMLSchema#string

P932

5678185

http://www.w3.org/2001/XMLSchema#string

Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.

about

P2860

P2860

Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P932